Responsiveness of skin metastases to CMF in a patient with urothelial carcinoma of the bladder: a case report

Tumori. 2003 Jan-Feb;89(1):85-7. doi: 10.1177/030089160308900118.

Abstract

Skin metastases from urothelial carcinoma of the bladder are uncommon, and there are few cases reported in literature. The present case report describes the results of a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) administered as second-line chemotherapy in a cisplatin-resistant metastatic bladder cancer patient. The improvement in cutaneous lesions and pain reduction obtained prompt further exploration of the activity of this regimen in a second-line approach.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / secondary*
  • Cisplatin / pharmacology
  • Cyclophosphamide / administration & dosage
  • Drug Resistance, Neoplasm
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Methotrexate / administration & dosage
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / secondary*
  • Treatment Outcome
  • Urinary Bladder Neoplasms / pathology*
  • Urothelium / pathology

Substances

  • Cyclophosphamide
  • Cisplatin
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF regimen